FAP iCDC therapy for advanced heart failure from dilated cardiomyopathy
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with dilated cardiomyopathy and heart failure with a weakened pumping ability.
- You have been on the best possible heart failure medications for at least 3 months.
- Your heart's ejection fraction is less than 35% and you have severe symptoms (NYHA class IIIB-IV).
- Your blood counts (hematocrit, lymphocytes, platelets) are above certain levels.
- You have not had a heart attack, stroke, or unstable angina in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
This trial tests a treatment made from stem cells that are turned into heart muscle cells and injected directly into the heart. It is for people with advanced heart failure who are already on the best available medicines and who are scheduled to have bypass surgery.
This trial uses a smartphone app to screen first-degree relatives of people with dilated cardiomyopathy (DCM) for early signs of the condition. It aims to detect heart muscle weakness before symptoms start, so that treatment can begin sooner.
This trial tests a special way to pace the heart and a procedure to quiet the irregular rhythm in people with advanced heart failure and long-standing atrial fibrillation. It may help improve symptoms and heart function, possibly reducing the need for a transplant.
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.